Related Experiment Video
Updated: Jun 5, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Stereotactic ablative radiation therapy for primary lung tumors
John H Heinzerling1, Brian Kavanagh, Robert D Timmerman
1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cancer Journal (Sudbury, Mass.)
|January 26, 2011
Summary
Stereotactic ablative radiotherapy is an effective treatment for stage I lung cancer in patients unable to undergo surgery. This review updates evidence on its use and associated toxicities.
Area of Science:
- Oncology
- Radiation Oncology
Background:
- Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT), is an advanced radiotherapy technique.
- It has been developed as an innovative therapy for stage I non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To review and update the evidence for SABR in medically inoperable patients with stage I lung cancer.
- To examine the extension of SABR use to medically operable patients.
- To summarize the toxicities associated with SABR for lung cancer.
Main Methods:
- Review of prospective, multi-institutional trials.
- Analysis of evidence for SABR in stage I NSCLC.
- Evaluation of toxicity data from clinical studies.
Main Results:
- SABR has emerged as a standard treatment option for medically inoperable patients with stage I NSCLC.
- Evidence supports the use of SABR in both medically inoperable and operable patients.
- The toxicities associated with SABR are generally manageable.
Conclusions:
- SABR is a well-established and effective treatment for stage I NSCLC, particularly in medically inoperable patients.
- The application of SABR is expanding to include medically operable patients.
- Understanding and managing SABR-related toxicities is crucial for optimal patient care.
